Market Trends And Expectations For Advanced Therapies In 2023

The cell and gene therapy space has undergone transformational change in the last few years, driven by the promise these modalities have demonstrated in addressing rare and intractable diseases. Achievements in the CAR-T therapy space – there are now six approved CAR-T treatments on the market – in conjunction with breakthroughs in gene therapy and viral vector drugs, have signaled a new era of innovation aimed at furthering cell and gene therapies within the greater healthcare landscape. A crucial component of this innovation centers on the cutting-edge technologies developed to support end-to-end therapeutic development, as well as the ever-evolving foundational science that continues to uncover new and novel modalities, processes, and analytical approaches.

In a recent panel discussion hosted by Precision ADVANCE, experts from across the cell and gene therapy sector convened to explore the ways their organizations have met headlong the challenges and opportunities that typify cell and gene therapy development. Cell and gene therapy is an incredibly complex field, with teams and sponsors developing therapies for broad therapeutic areas and disparate, difficult rare diseases. This year is likely to yield a number of key advancements for the space, owing to the continued collaboration of players across a wide range of scientific and medical disciplines and teams.